Corvus Pharmaceuticals Inc (CRVS)
1.92
+0.19
(+10.98%)
USD |
NASDAQ |
May 03, 16:00
2.05
+0.13
(+6.77%)
After-Hours: 20:00
Corvus Pharmaceuticals Enterprise Value: 67.01M for May 3, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
May 03, 2024 | 67.01M |
May 02, 2024 | 57.69M |
May 01, 2024 | 51.80M |
April 30, 2024 | 48.86M |
April 29, 2024 | 50.33M |
April 26, 2024 | 43.96M |
April 25, 2024 | 45.43M |
April 24, 2024 | 46.90M |
April 23, 2024 | 47.88M |
April 22, 2024 | 43.47M |
April 19, 2024 | 41.50M |
April 18, 2024 | 42.00M |
April 17, 2024 | 39.54M |
April 16, 2024 | 44.94M |
April 15, 2024 | 44.94M |
April 12, 2024 | 47.88M |
April 11, 2024 | 49.35M |
April 10, 2024 | 46.90M |
April 09, 2024 | 52.78M |
April 08, 2024 | 56.71M |
April 05, 2024 | 58.67M |
April 04, 2024 | 55.73M |
April 03, 2024 | 58.67M |
April 02, 2024 | 64.06M |
April 01, 2024 | 64.06M |
Date | Value |
---|---|
March 28, 2024 | 60.14M |
March 27, 2024 | 60.63M |
March 26, 2024 | 59.16M |
March 25, 2024 | 59.16M |
March 22, 2024 | 60.63M |
March 21, 2024 | 63.08M |
March 20, 2024 | 63.57M |
March 19, 2024 | 68.97M |
March 18, 2024 | 66.02M |
March 15, 2024 | 66.02M |
March 14, 2024 | 65.04M |
March 13, 2024 | 70.93M |
March 12, 2024 | 71.91M |
March 11, 2024 | 71.42M |
March 08, 2024 | 76.81M |
March 07, 2024 | 84.66M |
March 06, 2024 | 78.28M |
March 05, 2024 | 76.32M |
March 04, 2024 | 78.77M |
March 01, 2024 | 79.76M |
February 29, 2024 | 82.70M |
February 28, 2024 | 85.64M |
February 27, 2024 | 88.58M |
February 26, 2024 | 85.64M |
February 23, 2024 | 88.09M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-26.95M
Minimum
Mar 16 2020
295.39M
Maximum
Sep 21 2021
36.53M
Average
33.26M
Median
Sep 03 2020
Enterprise Value Benchmarks
Cyclacel Pharmaceuticals Inc | -0.7414M |
Arbutus Biopharma Corp | 362.27M |
Oragenics Inc | 3.216M |
Relmada Therapeutics Inc | 14.72M |
MAIA Biotechnology Inc | 60.36M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -6.653M |
Total Expenses (Quarterly) | 5.651M |
EPS Diluted (Quarterly) | -0.13 |
Earnings Yield | -29.17% |